Tag: Psoriasis
The American College of Rheumatology, Nov. 3-8
The 81st Annual Meeting of the American College of Rheumatology The annual meeting of the American College of Rheumatology was held...
Tofacitinib Superior to Placebo in Active Psoriatic Arthritis
Tofacitinib is superior for patients with inadequate response to TNF inhibitors or conventional DMARDs
Secukinumab Effective for Moderate/Severe Scalp Psoriasis
Over half of patients have 90 percent improvement on Psoriasis Scalp Severity Index score
Noninvasive Test for NASH, Fibrosis in Patients With Psoriasis
Correlation for cumulative methotrexate dose with higher score on NASH FibroSure in women
ABP 501, Adalimumab Biosimilar, Safe and Effective, for Psoriasis
Findings based on comparison over 52 weeks, including single transition
Tofacitinib Associated With Improvement in Nail Psoriasis
Improvement in nail psoriasis severity at 16 weeks versus placebo; maintained through 52 weeks
Ixekizumab Improves Symptoms in Patients With Psoriatic Arthritis
Two-week and four-week ixekizumab dosing regimens improved signs and symptoms
Uveitis Risk Higher Among Individuals With Psoriasis
Increased risk with severe psoriasis, mild psoriasis with psoriatic arthritis
Specific Factors Influence First-Line Biologic Rx for Psoriasis
Presence of psoriatic arthritis, weight, employment status, baseline disease severity all affect selection
Lower Psoriasis Area, Severity Scores for Women Versus Men
No differences in medication use before enrollment could explain these gender differences
